| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 430 | 620 | 560 | 540 | 770 |
| Sales Growth | -30.65% | +10.71% | +3.70% | -29.87% | +22.22% |
| Net Income | -22,210 | -20,830 | -21,860 | -19,440 | -21,790 |
| Net Income Growth | -6.63% | +4.71% | -12.45% | +10.78% | -16.46% |
Anteris Technologies Global Corp
(AVR)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Anteris Technologies Global Corp. is involved in designing, developing and commercializing cutting-edge medical devices to restore healthy heart function. The company's lead product includes DurAVR(R). Anteris Technologies Global Corp. is based in BRISBANE, Australia.
Fiscal Year End Date: 12/31